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cal models of mammalian ventricular cells (dynamic Luo Rudy formulation) and early 
(myoblast) and late (myofiber) differentiated skeletal cells. The strands were either 
homogenous, or of mixed (half/half) cardiac and skeletal myofiber forms. They were used 
to explore coupling requirements and effects of action potential morphology on ventricu- 
lar-sketstal interaction. 
RESULTS: The action potential duration (APE)) of skeletal cells is short (2.5 ms) and is 
the major limitation of skeletal-to-skeletal and skeletal-to-cardiac excitation. A high 
degree of intercellular coupling was required for skeletal cells to excite their downstream 
neighbors quickly enough, within 2.5 ms, prior to there own repoladzation. The cardiac 
APD is long (178 ms) and there was a long length of time for cardiac cells to charge their 
downstream neighbor, before the charging cell repoladzes. Decreasing intercellular cou- 
pling increased the time necessary to charge adjoining cells. The ratio of intercellular 
coupling reduction to still allow cell-to-cell excitation in homogeneous trands was 45:5:1 
for the ventricular, skeletal myoblast, and skeletal myofiber cell types, respectively. In 
mixed strands, the limiting factor in excitation was any instance that the skeletal cell was 
the source cell. 
CONCLUSION: Skeletal cells need a very high degree of coupling to their neighbors and 
to ventricular myocardium for adequate call-to-cell action potential flow. Gene therapy 
based interventions that prolong the skeletal APD such as introducing a slow inward cal- 
cium current, or use of cells with action potentials longer than 3 ms, would decrease this 
coupling requirement. 
1204-145 Compar i son  of  the  Ef fects  of  L is inopr i l  and a Prolyl 4- 
Hydroxylase Inhibitor (FG041) on Left Ventricular 
Function After Acute Myocardial Infarction 
John I. Nwoau, Maurice Bean, David L Geenen, Jay Bagai, Ajanta De, Beth E. Reed, 
Mehdi Nafissi, Mitchell Brenner, Peter M. Buttrick, University of Illinois at Chicago, 
Chicago, Illinois, Fibrogen INC, South San Francisco, California. 
Background: We have previously shown that proly 4- hydroxylase (P4H) inhibition by 
FG041, which specifically inhibits collagen biosynthesis when given after myocardial inf- 
arction (MI) decreases fibrosis, and improves left ventricular function (LVEF) and sur- 
vival. ACE inhibitors decrease fibrosis and produce similar beneficial effects. It is unclear 
if ACE inhibitors and P4H inhibitors will produce similar and complementary effects on LV 
function post MI. Method: Rats who underwent left coronary artery ligation to produce MI 
were randomized to Lisinopril (Lie, n=13, at 15mg/kg QD) and FG041 (P4H, n=13,at 
50mg/kg BID), Lisinopril and FG041 at same dose (LisP4H, n=10) and to vehicle (con, 
n=13). Echo was performed weekly for 4 weeks then biweekly till week 8 using a 15 mHz 
Linear probe, Results: At randomization, LV function and dimensions were similar in aH 
groups. P4H and Lis produced similar improvement in LVEF compared to control (P<0.05 
weeks 2-6, P =NS week 8). Combination therapy produced a more favorable effect on 
LVEF (see figure P<O.05 weeks 2-8 vs. con) and LV diastolic function (mitral inflow veloc- 
ity 0.97m/s vs. 1.34m/s in con, p=0.028). Conclusion: Our data shows that FG041 and 
Lisinopril produced similar improvement in LVEF while combination therapy produced 
greater improvement in LV systolic and diastolic functions. Thus the two agents have 
comparable and complementary effects on LV function post MI. 
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1205-137 Atlas: Do Gender Differences Affect Outcome Results? 
Mareo M. Schleman. AstraZeneca LP , Clinical Research, Wayne, Pennsylvania. 
Background: The Assessment of Treatment with Lisinopdl (L) and Survival (ATLAS) trial 
found high dose L (32.5-35 mg) reduced combined endpoint of deaths and hospitaliza- 
tions by 12% (p=0.0002) and trended to a reduction in all cause mortality by 8% 
(p=0.128). Women (n=648) comprised 20% of patient poulation. This retrospective anal- 
ysis examined whether gender differences were present in demography, outcome 
results, or tolerabilty. Methods: A retrospective analysis of ATLAS data base was made 
based on gender and high and low dose L. Descriptive statistics were applied and an 
arbitrary cut off of 10% was used to identify differences. Results: Demography; Women 
had more history of hypertension than men (48% vs 19.4%) and men had more history of 
ischemic heart disease than women (67.5% vs 52%). Baseline systolic BP was higher in 
women (123.1 mmHg vs 119.4 mmHg). El:, NYHA class, DBP, and previous ACE inhibi- 
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tor use were similar in both groups. Outcome results; All cause mortality hazard ratio 
(HR) for L (high dose :low dose) was neutral in women(HR=1.054, p=0.677) but trended 
positively in men (HR=0.891, p=0.053). Total mortality on either L dose in men was 1130 
(45%) compared to 253 (39%) in women. HR for mortality plus hospitalizations was 
favorable in both women and men, HR=0.829, p=0.033 in women and HR=0.899, 
p=0.016 in men. Tolerability; High dose L was generally well tolerated in both men and 
women. Drop outs related to an Adverse Event (AE) occurred in 115 women (17.7%) and 
in 439 men (17.4%) with CHF and dyspnea the most frequently observed AEs (17%- 
28%). Increased cough occurred more frequently in women (high dose 14.8%, low dose 
18.1%) than men (high dose 9.5%, low dose 11.9%) and sudden death was noted more 
frequently in men (high dose 15.1%, low dose 16%) than women (high dose11%, low 
dose 10.3%). Conclusion: High dose L was beneficial in men and women in reducing 
mortality plus hospitalizations. A strong trend (p=0.053) towards reducing mortality bene- 
fit in men was observed but not in women. A larger study in women is needed to defini- 
tively evaluate the response in mortality on high dose L. The overall results of ATLAS 
suggest uptitretion of L is of benefit to both men and women. 
1205-1 38 Prognostic Importance of a Wide QRS Complex in 
Asymptomatic Patients with Depressed Left Ventricular 
Function in Predicting Morta l i ty  
Sunny Srivastava, Amin AI-Ahmad, Munther K. Homoud, Mark S. Link, N.A. Mark Estes, 
III, Marvin A. Konstam, Paul J. Wang, Deed N. Salem, New England Medical Center, 
Boston, Massachusetts. 
Background: A wide QRS complex in patients with clinical heart failure is a potent predic- 
tor of death. However, the prognostic value of a wide QRS complex in asymptomatic 
patients with depressed left ventricular function is not known. 
Methods: We performed a retrospective analysis on the 4228 patients enrolled in the 
Studies of Left Ventdcular Dysfunction Prevention Trial. All patients had a left ventricutar 
ejection fraction (LVEF) < 35% (mean 28.3%). The mean follow up was 32+/-15 months. 
QRS duration was noted to be > 120ms in 1186 patients and < 120ms in 2292 patients 
upon enrollment into the trial, A QRS duration > 120ms was evaluated as a predictor of 
all cause mortality univariata analysis with a Log-rank statistic. A Cox regression model 
was constructed for multivariate analysis with covariates that included LVEF, age, medi- 
cation and medical history. 
Results: A QRS duration > 120ms was not associated with an increased risk of death 
(univadate p = 0.3t, multivariate p = 0.46). 
Conclusions: In contrast o patients with clinical heart failure, in patients with asymptom- 
atic left ventricular dysfunction QRS duration does not appear to be a predictor for mor- 
tality. 
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1205-140 impact of South Asian (SA) Ethnicity On Presentation 
and Outcomes Following Hospitalization for Congestive 
Heart Fai lure (CHF) 
Narendra Sinoh, Milan Gupta, Tuhina Biswas, Quak M. Nguyen, Rouge Valley Health 
System-CHC site, Toronto, Ontario, Canada, William Osier Health Centre-Brampton 
campus, Brampton, Ontario, Canada. 
SA develop CAD at a younger age and have larger Ml's compared to European Canadi- 
ans (EU). We hypothesized that SA would therefore also develop CHF at a younger age. 
A retrospective review of 887 consecutive pts admitted between 1997-99 to 2 large com- 
munity hospitals with a primary diagnosis of CHF was performed. 
Results: CAD was the primary etiology of CHF in both groups (49 vs 48%). Pts with car- 
diac enzymes > 2 times normal were excluded. 99 (11%) of pts were SA and 728 (79%) 
were EU based on name analysis. 51% were males. SA were much younger (69.1 vs 
75.1yrs, p=.000017), had more diabetes (57 vs 39% p<,001), were less likely smokers 
(24% vs 41% p<.01 ) had lower body mass index (24.4 vs 26.7kg/m2, p=.003), but similar 
hypercholesterolemia (27 vs 22%), hypertension (62 vs 59%), and family history of CAD 
(10 vs 9%). Prior history of CHF was similar in both groups (57 vs 58%) with the average 
ejection fraction also being similar (40 vs 42%). 
On presentation, HR (98.1vs95.7 bpm p=0.4) and BP (139/82 vs 138/77, p=.02) trended 
higher in SA. Serum sodium was lower (135 vs 137mmol, p=,0002). Initial (150 vs 
135mmol, p=0.1) and discharge creatinine (172 vs 144mmol, p=.014) were higher in SA. 
Most in-hospital complication rates were similar but SA had more ventdcular arrhythmias/ 
cardiac arrest (10 vs 5%, p<.05) and less afib (15 vs 24% p<.05). Unadjusted mortality 
was similar (6 vs 11%, p=ns). Evidence-based drug therapies were used with similar fre- 
quency. Overall 66% received ACEVARB, 84% diuretic, 20% beta blockers, 17% 
spironolactone and 11% statins. 
Conclusion Substantial differences at presentation are seen in SA pts hospitalized for 
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CHF. Despite being significantly younger, they presented with high risk features and had 
a higher in hospital complication rate although similar unadjusted mortality rate. This 
study suggests that pts of SA ethnicity are a high risk subset of the CHF population who 
may benefit from more aggressive therapeutic intervention at an eedier age. 
1205-155 Mltral  Regurg i tat ion Is an Independent Risk Factor fo r  
Mortality in Patients With Heart Failure and Left  
Ventr icu lar  Systo l i c  Dysfunction 
Beniamin H. Tdchon, G. Michael Felker, Linda K. Shaw, Christopher H. Cabell, 
Christopher M. O'Connor, Duke Clinical Research Institute, Durham, North Carolina. 
Background: Mitral regurgitation (MR) is common in patients with heart failure (HF). 
However, mild MR accompanying left-ventdcular (LV) dysfunction is often minimized in 
practice and the relation between the severity of MR and survival is not well character- 
ized. 
Methods: We assessed the incidence of MR in patients with HF (-> NYHA II) and ejection 
fraction @,0% undergoing cardiac catheterization between 1986 and 2000. MR was 
graded as mild (grade 1+/2+) or moderate/severe (grade 3+/4+). 
Patients with other valvular disease were excluded. Baseline charactedstics of the popu- 
lation were defined. A multivariate Cox proportional hazards model was used to assess 
the independent effect of MR on survival. 
Results: 2057 patients met study cdteria. 1156 (56%) had MR identified. In 811 (70%), 
the MR was mild. Patients with MR were more likely to be older (63 vs. 60, p=O.001), 
female (43.4% vs. 28.9%, p=0.001), and have a gallop on exam (36.5% vs. 24.8%, 
p--O.001). Mean duration of follow-up = 3.4 years. 
Compared to those without MR, patients with mild and moderate/severe MR had an 18% 
(HR=1.18, 1.03-1.36, p=0.01) and 53% (HR=1.53, 1.29-1.82, p<0.001) increased risk of 
death, respectively (GRAPH). 
Conclusions: 
MR is common in patients with HF and systolic dysfunction. There is an independent, 
progressive relation between MR severity and mortality. Studies are needed to investi- 
gate the affect of therapies (mltral valve repair or cardiac re-synchronization) on out- 
comes in patients with MR accompanying LV dysfunction. 
MR Grade  and  eur~rlVal  In HF  Pa l te r  
1205-156 Prognosis of Women Compared With Men With Heart 
Failure end Acute Myocardial Infarction After Previous 
Revascularlzatlon 
Predrao M. Mitrovic, Zorana Vaslljevic-Pokrajcic, Branislav Stefanovic, Jovan Perunicic, 
Gordana Matic, Nebojse Radovanovic, Dubravka Rajic, Cardiology Clinic, institute for 
Cardiovascular Diseases, University Clinical Centre, Belgrade, Yugoslavia. 
Patients (pts) who have clinical evidence of congestive heart failure (CHF) after acute 
myocardial infarction (AMI) and previous coronary artery bypass grafting (CABG) have a 
poor prognosis. The aim of this prospective study was to analyze influence of gender on 
survival in pts with CHF and AMI after previous CABG. Methods: From April 1990 - 
August 2001 we studied 730 pts, who developed AMI after CABG, mean age 58.4+8.0 
years, mainly men (80.8%). The pts with eerly perioperative AMI were excluded from the 
study. All pts were followed-up 12 years. The average time interval from CABS to AMI 
was 96.2 ± 16.0 months. The average number of grafts was 3,4 grafts/pts. There were 
274/730 pts (37.5%) with signs of CHF. Clinical evidence of CHF was defined as at least 
two of the following: bibasilar ralas, third heart sound or/and interstitial or alveolar edema 
on chest radiograph. All pts were divided in two groups: group I - 89/274 (32.5%) female 
with CHF and AMI after previous CABG and group II - 185/274 (67,5%) male with CHF 
and AMI after previous CABG. Results: There was no statistical difference in age, 
CABG-AMI interval, number of grafts/pie, AMI location, infarct size and risk factors for 
coronary artery disease. There were differences between groups in: previous angina 
pectods (91% vs 56.8%, p<0.01), previous AMI (56.2% vs 31.3%, p<0.05), in-hospital 
mortality (15.7% vs 4.3%, p<0,05) and one-year mortality (40.4% vs 11.9%, p<0.01). 
Conclusion: This study suggests that female with signs of CHF and AMI after previous 
CABG had worse prognosis compared with male with CHF and AMI after previous 
CABG, specially in in-hospital and one-year padod; the predictors of that prognosis were 
previous angina pectods and previous AMI. 
1205-157 The Incremental Prognostic Sign i f i cance of  
Hyperurlcemla In African Americana With Severe Heart 
Fai lure 
Patricia A. Uber. Mandeep R. Mehra, Myung H. Park, Robert L. Scott, Ochsner 
Cardiomyopathy and Heart Transplantation Center, New Orleans, Louisiana. 
Background: Compared with Caucasians (C), African Americans (AA)exhibit higher uric 
acid levels, a marker of free radical generation. We sought to determine the clinical 
impact of hyperuricamia in AA with severe Heart Failure (HF).Methoda: 140 severe HF 
patients (52 +11 years, ejection fraction 20 :L-9%, 80% men, follow-up 12-72 months) 
awaiting heart transplantation were examined in order to evaluate the prognostic utility of 
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baseline uric acid levels (_>7.5 versus < 7.5 mg/dl) at listing for transplantation, as a func- 
tion of race. We analyzed detailed variables among the 106 C and 34 AA patients to 
assess variables predictive of HF hospitalizations or death in concert with hyperurice- 
mia.Reaulta: Baseline charactedstics were similar in AA and C with regard to age, EF%, 
NYHA class, serum sodium, bilirubin, creatinine and HF medications. AA were more 
likely than C's to, have hypertension (61% vs 40%, p =0.04), had a larger proportion of 
women (39% vs 13%, p = 0.007), and were more hyperudcemic (7.9 + 2.1 vs 6.8 ± 2.0, p 
= 0.006). The results of actuarial event free survival at 3 years are shown in the table. 
Group African Americana Caucasians p value 
Urlc Acld > 7.5mg/ 60% 71% 0.04 
dl 
Uric Acid < 7.5 rag/ 86% 80% ns 
dl 
p value 0.03 ns 
Multivariable analysis demonstrated that hyparudcamia occurred independent of diuretic 
use, renal function, age and gender.Conclusions: Hyperuricamia, a marker of oxidative 
stress, is prevalent in AA and represents a discriminatory marker of poor clinical outcome 
in severe HF. This investigation provides insight into ethnic differences in oxidative stress 
as a critical determinant of prognosis in heart failure. 
1205-158 Predict ion of  Morbidity and Morta l i ty  Fo l lowing 
Myocardial Infarction 
Kenneth Dickstain, Stevan Snappin, The OPTIMAAL Trial Study Group, Central Hospital 
in Rogaiand, Stavanger, Norway. 
Introduction: It is important to choose the most appropriata endpoints in clinical trials 
evaluating an intervention on morbidity and mortality. The ability of these events to pre- 
dict death impacts on patient selection and trial design. 
Methods: 5477 patients with acute myocardial infarction and left ventricular dysfunction 
have been randomised to treatment with either captopdl or Iosertan in the OPTIMAAL 
trial. During a mean follow-up period of 27 months there have been 584 patients with 
reinfarctions, 1561 patients with ravascularisation (PTCA/CABG), 2670 patients with car- 
diovascular (CV) hospltalisations and 780 deaths. 
Results; Baseline demographics contain powerful predictors for reinfarction, revascular- 
isation or hcspitalisetion. The ability of selected variables to predict a heart failure (HF) 
hospitalisation are displayed in the table. The increases in risk of death associated with 
cardiovascular endpoints were: HF hospitalisetion 746%, Rainfarction 502%, CV Hospi- 
talisation 290%, Revasculadsation -45% (P<0.001 in all cases). 
Conclusion: Morbid events following complicated MI are predicted by selected baseline 
demographic variables. Death is predicted by these morbid endpoints. A heart failure 
hospitalisetion was an especially powerful predictor for death. These data have implica- 
tions for the choice of patients and endpoints in clinical tdals seeking to assess the effi- 
cacy of an intervention on morbidity and mortality. 
Increases In Risk of a Heart Failure Hoapltalleatlon 
Baseline Risk Factor Clinical Status Prior to Randomization 
age (per year) 6% tachycardia 83% 
diabetes 62% X-ray congestion 81% 
atrial fibrillation 62% IV diuretics 77% 
prior diuretic 62% pulmonary rales 60% 
previous infarction 47% EF<35% 52% 
previous infarction 41% gallop rhythm 48% 
prior beta blocker 39% Killip class (per class) 58% 
P<O.O01 in all cases 
1205-159 Low Serum Total Cholesterol Is Associated With a 
Marked Increase in Mortality in Advanced Heart Fai lure 
Tamare B. Herwich, Machete A. Hamilton, Robb MacLellan, Gregg C, Fonarow, UCLA 
Medical Center, Los Angeles, California. 
Background: Although hypercholesterolemia is associated with CAD and cardiovascu- 
lar mortality, the relationship between choleeterot and heart failure (HF) mortality is less 
certain. 
Methods: Our study analyzed 1134 patients with advanced HF referred to a single cen- 
ter for transplant evaluation. The cohort was 75% men, etiology was 48% ischemic, and 
mean EF was 22%. Serum lipid panel was measured time of initial presentation. Patients 
were stratified into five groups based on quintiles of total cholesterol (TC) level. 
Resulta: HF etiology, HTN, DM, and lipid-lowering therapy at time of referral were similar 
among the 5 TC groups. Patients with lower TC had significantly lower levels of LDL, 
HDL, triglycarides (TG), sodium and albumin. The lower TC quintiles had lower EF and 
cardiac output, but higher wedge pressures and increased likelihood of NYHA class IV. 
Decreased TC, LDL, HDL, and TG each predicted increased mortality (p=0.01) on 
univadate analysis. After adjustment for known predictors of HF mortality including BMI, 
elevated TC was an independent predictor of improved survival (0.996 RR tor lmg/di 
increase), while LDL, HDL, and TG were not. See table for survival and relative dsk of 
each TC quintile. 
Conclusions: Low serum TC predicts HF outcomes independent of established mortality 
predictors, and thus represents a novel prognostic factor. Further investigations are nec- 
essary to determine whether a low TC level is merely a prognostic marker or is playing a 
causative role in HF mortality. 
